What is Semba Biosciences?
Semba Biosciences, founded in 2005 and headquartered in Madison, Wisconsin, is a life science company specializing in the development and application of continuous chromatography systems. The company's proprietary Octave® Systems are designed for efficient and scalable purification of biomolecules, serving the food, chemical, and pharmaceutical industries. With the introduction of Octave® BIO and ProGMP products, Semba Biosciences is extending its innovative continuous chromatography solutions to the biopharmaceutical industry, targeting downstream process development and single-use manufacturing applications. The company's commitment to advancing purification technologies positions it as a key player in enabling more efficient bioprocessing.
How much funding has Semba Biosciences raised?
Semba Biosciences has raised a total of $330K across 2 funding rounds:
Debt
$150K
Debt
$180K
Debt (2020): $150K with participation from PPP
Debt (2021): $180K led by PPP
What's next for Semba Biosciences?
The recent strategic investment signifies a pivotal moment for Semba Biosciences, likely enabling the company to accelerate its go-to-market strategy for its biopharmaceutical-focused solutions. This capital infusion is expected to support expanded manufacturing capabilities, further research and development into next-generation chromatography technologies, and broader market penetration within the rapidly growing biopharmaceutical sector. The company's focus on continuous chromatography for both development and GMP manufacturing suggests a strategic aim to capture a significant share of the bioprocessing market by offering scalable and cost-effective purification solutions.
See full Semba Biosciences company page
